Source: Eur Respir J 2002; 19: 912-918
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Libura J., Bettens F., Radkowski A., Tiercy J.M., Piguet P.F.. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur Respir J 2002; 19: 912-918

Member's Comments

No comment yet.

Related content which might interest you: Tumour necrosis factor-α and lymphotoxin-α gene polymorphisms in cystic fibrosis lung disease Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Clinical course of cystic fibrosis lung disease and tumour necrosis factor-β gene polymorphism Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008 Tumor necrosis factor-α gene polymorphism and inflammatory process in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 403s Year: 2005 Tumor necrosis factor-alpha and CD4/CD8 ratio in patients with hypersensitivity pneumonitis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis Source: Eur Respir J 2003; 21: 421-428 Year: 2003 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006 Tumor necrosis factor α in chronic pulmonary diseases of children Source: Eur Respir J 2002; 20: Suppl. 38, 193s Year: 2002 Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Correlation of IL-1 alpha and IL-4 promotor region gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease Year: 2006 Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 Role of tumour necrosis factor-α receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema Source: Eur Respir J 2006; 28: 102-112 Year: 2006 Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016 Analysis of tumor necrosis factor receptor 1 (TNFR1) polymorphisms in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 411s Year: 2001 B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013